Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Bonella (Essen, Germany), T. Maher (London, United Kingdom), V. Cottin (Lyon, France), C. Valenzuela (Madrid, Spain), M. Wijsenbeek (Rotterdam, Netherlands), F. Voss (Ingelheim am Rhein, Germany), K. Rohr (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany). Consistent effect of nintedanib on reducing FVC decline across interstitial lung diseases (ILDs). 739

Member's Comments

No comment yet.

Related content which might interest you: Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015 Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC)<50% treated with pirfenidone (PFD) in RECAP Source: International Congress 2016 – IPF treatment I Year: 2016 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids? Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib Source: International Congress 2015 – Treatment of IPF Year: 2015 TNFα and INFγ inducing capacity of sera from interstitial lung diseases (ILD) patients in relation to its angiogenic activity Source: Eur Respir J 2001; 18: Suppl. 33, 410s Year: 2001 Influence of smoking habit on static lung compliance (Cst) in interstitial lung diseases (ILD) patients Source: Eur Respir J 2002; 20: Suppl. 38, 194s Year: 2002 Annual rate of FVC decline in patients with IPF treated with pirfenidone: Pooled analysis from 3 pivotal studies Source: International Congress 2016 – IPF treatment I Year: 2016 Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Reduced anti-oxidant and increased inflammatory status in interstitial lung diseases (ILD) Source: Eur Respir J 2007; 30: Suppl. 51, 110s Year: 2007 Effect of anti-acid medication on reduction in FVC decline with nintedanib Source: International Congress 2015 – Treatment of IPF Year: 2015 Correlation between spirometric indices (FEV1, FVC) and lung diffusion values (DLCO) in subjects with varying severity of chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2007 - Primary care respiratory problems Year: 2007 Exercise limitation in patients with interstitial lung disease independent from diffusion capacity (DLCO) Source: Annual Congress 2008 - Exercise: system responses Year: 2008 Is radiologic evidence of interstitial infiltrate enough to predict FEV1 and DLCO disparity in lung cancer patients? Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 The role of concomitant respiratory diseases on the rate of decline in FEV1 among adult asthmatics Source: Eur Respir J 2003; 21: 95-10 Year: 2003 Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trial Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 Static lung compliance (Cst) and diffusion lung capacity (DLCO) as markers of lung function impairment in sarcoid patients with normal lung volumes Source: Eur Respir J 2003; 22: Suppl. 45, 278s Year: 2003 Short-term dynamic lung function and predictors of lung function decline in systemic sclerosis-related interstitial lung disease Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020